Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial

Acta Oncologica

Volumn 54, Issue 10, 2015, Pages 1747-1753

  Jakobsen, Anders ^a,d   Andersen, Fahimeh ^b   Fischer, Anders ^c   Jensen, Lars H ^a   Jørgensen, Jens C R ^a   Larsen, Ole ^c   Lindebjerg, Jan ^a   Pløen, John ^a   Rafaelsen, Søren R ^a,d   Vilandt, Jesper ^b  

^a LILLEBAELT HOSPITAL   (Denmark)

^b HILLERØD HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CAPECITABINE; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; PIK3CA PROTEIN; PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PLATINUM COMPLEX; PROTEIN P21;

ABDOMINAL ABSCESS; ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANASTOMOSIS LEAKAGE; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DISTANT METASTASIS; DRUG DOSE REDUCTION; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GENE MUTATION; HIGH RISK PATIENT; HUMAN; ILEUS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OVERALL SURVIVAL; PARESTHESIA; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RECURRENCE RISK; SKIN TOXICITY; WOUND DEHISCENCE; ADENOCARCINOMA; CANCER STAGING; CLINICAL TRIAL; COLONIC NEOPLASMS; DISEASE FREE SURVIVAL; GENETICS; MUTATION; NEOADJUVANT THERAPY; PATHOLOGY; RADIOGRAPHY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPECITABINE; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MUTATION; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84946202374     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2015.1037007     Document Type: Article

References (25)

1. Hohenberger W, Weber K, Matzel K, Papadopoulos T, Merkel S. Standardized surgery for colonic cancer: Complete mesocolic excision and central ligation-technical notes and outcome. Colorectal Dis 2009; 11: 354-64.
2. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-51.
3. Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev 2008; 3:C D005390.
4. OConnor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 2011; 29: 3381-8.
5. Benson III Al B, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408-19.
6. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the Mosaic trial. J Clin Oncol 2009; 27: 3109-16.
7. Tournigand C, André T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: Subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant treatment of colon cancer trial. J Clin Oncol 2012; 30: 3353-60.
8. Yothers G, OConnell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011; 29: 3768-74.
9. Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2-to 11-year colorectal cancer survivors: Results from the population-based PROFILES registry. J Clin Oncol 2013; 31: 2699-707.
10. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: A randomized trial. JAMA 2012; 307: 1383-93.
11. Allegra CJ, Yothers G, OConnell MJ, Sharif S, Petrelli NJ, Lopa SH, et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol 2013; 31: 359-64.
12. Smith NJ, Bees N, Barbachano Y, Norman AR, Swift RI, Brown G. Preoperative computed tomography staging of nonmetastatic colon cancer predicts outcome: Implications for clinical trials. Br J Cancer 2007; 96: 1030-6.
13. Dighe S, Blake H, Koh MD, Swift I, Arnaout A, Temple L, et al. Accuracy of multidetector computed tomography in identifying poor prognostic factors in colonic cancer. Br J Surg 2010; 97: 1407-15.
14. Dighe S, Purkayastha S, Swift I, Tekkis PP, Darzi A, AHern R, et al. Diagnostic precision of CT in local staging of colon cancers: A meta-analysis. Clin Radiol 2010; 65: 708-19.
15. Dighe S, Swift I, Magill L, Handley K, Gray R, Quirke P, et al. Accuracy of radiological staging in identifying high-risk colon cancer patients suitable for neoadjuvant chemotherapy: A multicentre experience. Colorectal Dis 2012; 14: 438-44.
16. Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: The pilot phase of a randomised controlled trial. Lancet Oncol 2012; 13: 1152-60.
17. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479-516.
18. Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res 2012; 18: 1177-85.
19. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
20. Nørgaard A, Dam C, Jakobsen A, Pløen J, Lindebjerg J, Rafaelsen SR. Selection of colon cancer patients for neoadjuvant chemotherapy by preoperative CT scan. Scand J Gastroenterol 2012; 49: 202-8.
21. Grothey A, Lenz HJ. Explaining the unexplainable: EGFR antibodies in colorectal cancer. J Clin Oncol 2012; 30: 1735-7.
22. Primrose JN, Falk S, Finch-Jones M, Valle JW, Sherlock D, Hornbuckle J, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: The New EPOC randomised controlled trial. Lancet Oncol 2014; 15: 601-11.
23. V600E mutation and its association with clinicopathological features of colorectal cancer: A systematic review and meta-analysis. PLOS One 2014; 9: e90607.
24. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009; 69: 1851-7.
25. Arredondo J, Pastor C, Baixauli J, Rodríguez J, González I, Vigil C, et al. Preliminary outcome of a treatment strategy based on perioperative chemotherapy and surgery in patients with locally advanced colon cancer. Colorectal Dis 2013; 15: 552-7.